Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3.0M of ENGN
owner at enGene Holdings Inc.. 470,633 shares at an average of $6.40, traded Dec 27, 2023, filed Oct 18, 2024.
Score components
- +12Role10% owner
- +25Trade size$3.0M at market
- +6Relative to holdingsHoldings up 24%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.4%, 3m -20.8%, 6m -55.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-115607, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 27, 2023 | POpen-market purchase Common Shares | +2,750 | $7.17 | $20k | 2,002,750 | Oct 18, 2024 |
| Dec 28, 2023 | POpen-market purchase Common Shares | +5,050 | $7.69 | $39k | 2,007,800 | Oct 18, 2024 |
| Dec 29, 2023 | POpen-market purchase Common Shares | +400 | $8.30 | $3,320 | 2,008,200 | Oct 18, 2024 |
| Dec 29, 2023 | POpen-market purchase Common Shares | +9,620 | $9.09 | $87k | 2,017,820 | Oct 18, 2024 |
| Sep 27, 2024 | POpen-market purchase Common Shares | +38,396 | $5.94 | $228k | 2,056,216 | Oct 18, 2024 |
| Sep 27, 2024 | POpen-market purchase Common Shares | +3,243 | $6.38 | $21k | 2,059,459 | Oct 18, 2024 |
| Sep 30, 2024 | POpen-market purchase Common Shares | +341,332 | $6.34 | $2.2M | 2,400,791 | Oct 18, 2024 |
| Oct 1, 2024 | POpen-market purchase Common Shares | +35,279 | $6.44 | $227k | 2,436,070 | Oct 18, 2024 |
| Oct 2, 2024 | POpen-market purchase Common Shares | +10,153 | $6.37 | $65k | 2,446,223 | Oct 18, 2024 |
| Oct 3, 2024 | POpen-market purchase Common Shares | +5,769 | $6.48 | $37k | 2,451,992 | Oct 18, 2024 |
| Oct 4, 2024 | POpen-market purchase Common Shares | +5,997 | $6.54 | $39k | 2,457,989 | Oct 18, 2024 |
| Oct 7, 2024 | POpen-market purchase Common Shares | +11,844 | $6.55 | $78k | 2,469,833 | Oct 18, 2024 |
| Oct 8, 2024 | POpen-market purchase Common Shares | +800 | $6.60 | $5,278 | 2,470,633 | Oct 18, 2024 |
Related signals
Other insiders at enGene Holdings Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | ENGNbuy enGene Holdings Inc. | William Grossman Interim Chief Medical Officer | $10k 5,102 shares | - | |
| 38Weak | ENGNbuy enGene Holdings Inc. | Forbion Growth Opportunities Fund I Cooperatief U.A. owner | $5.0M 561,797 shares | +23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.